(NASDAQ: ALXN) today announced that the European Commission (EC) has approved the extension of the current marketing authorization of SOLIRIS (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.
- Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder
Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study.
The US Food and Drug Administration approved SOLIRIS (eculizumab) for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) in adult patients who are anti-aquaporin-4 antibody positive on June 27, 2019.
The US Food and Drug Administration (FDA) has approved United States-based Alexion Pharmaceuticals' (NASDAQ: ALXN) Soliris intended to treat adults with neuromyelitis optica spectrum disorder (NMOSD), a rare and severe autoimmune disease, who are anti-aquaporin-four antibody positive, it was reported on Friday.
Food and Drug Administration has approved Soliris (eculizumab) injection as the first treatment for neuromyelitis optica spectrum disorder (NMOSD), the agency announced Thursday.
Food and Drug Administration approved Soliris injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder, or NMOSD, in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.